BlackRock Inc. increased its holdings in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 2.9% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 2,433,000 shares of the biotechnology company’s stock after purchasing an additional 68,564 shares during the period. BlackRock Inc. owned about 0.13% of Enanta Pharmaceuticals worth $281,985,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in ENTA. Meadow Creek Investment Management LLC purchased a new stake in Enanta Pharmaceuticals during the 1st quarter valued at about $110,000. SG Americas Securities LLC purchased a new stake in Enanta Pharmaceuticals during the 1st quarter valued at about $112,000. Riverhead Capital Management LLC purchased a new stake in Enanta Pharmaceuticals during the 1st quarter valued at about $129,000. Glen Harbor Capital Management LLC purchased a new stake in Enanta Pharmaceuticals during the 1st quarter valued at about $140,000. Finally, Sei Investments Co. grew its stake in Enanta Pharmaceuticals by 63,966.7% during the 1st quarter. Sei Investments Co. now owns 1,922 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 1,919 shares during the last quarter. Hedge funds and other institutional investors own 77.62% of the company’s stock.
Several analysts have weighed in on ENTA shares. BidaskClub downgraded Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 23rd. Oppenheimer started coverage on Enanta Pharmaceuticals in a research note on Thursday, May 24th. They set a “buy” rating and a $135.00 price target on the stock. Roth Capital started coverage on Enanta Pharmaceuticals in a research note on Wednesday, June 6th. They set a “buy” rating and a $133.00 price target on the stock. Zacks Investment Research cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 4th. Finally, JMP Securities reissued a “buy” rating and issued a $120.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, July 31st. Six research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $107.60.
In related news, insider Jay R. Luly sold 35,000 shares of the company’s stock in a transaction dated Friday, July 6th. The stock was sold at an average price of $125.24, for a total value of $4,383,400.00. Following the completion of the transaction, the insider now owns 625,049 shares of the company’s stock, valued at approximately $78,281,136.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Nathalie Adda sold 4,155 shares of the company’s stock in a transaction dated Monday, August 20th. The stock was sold at an average price of $92.32, for a total value of $383,589.60. Following the completion of the transaction, the vice president now directly owns 4,465 shares of the company’s stock, valued at approximately $412,208.80. The disclosure for this sale can be found here. In the last three months, insiders sold 44,200 shares of company stock valued at $5,396,807. Insiders own 10.56% of the company’s stock.
Shares of ENTA stock opened at $91.74 on Tuesday. The stock has a market capitalization of $1.73 billion, a PE ratio of 100.81 and a beta of 0.87. Enanta Pharmaceuticals Inc has a 52-week low of $42.49 and a 52-week high of $127.77.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.98 by ($0.01). The company had revenue of $57.26 million during the quarter, compared to analyst estimates of $56.59 million. Enanta Pharmaceuticals had a net margin of 37.63% and a return on equity of 25.84%. sell-side analysts expect that Enanta Pharmaceuticals Inc will post 3.56 earnings per share for the current year.
Enanta Pharmaceuticals Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Recommended Story: Understanding Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.